Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CN NMPA Approves Innovent Biologics' GLP-1 Weight Loss Drug for Marketing
Recommend 4 Positive 7 Negative 0 |
||||
|
||||
|
China's National Medical Products Administration (NMPA) has recently approved the market launch of Innovent Biologics (Suzhou)'s Class 1 innovative drug Mazdutide injection. This drug is a dual receptor agonist for glucagon and glucagon-like peptide-1 (GLP-1), indicated for long-term weight management in adult patients, in conjunction with dietary control and increased physical activity, who also have at least one weight-related comorbidity (such as hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome). AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
